Shuhui W. Deng

Tianjin, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 83 publications

Circulating tumor cells identify a disseminated genomic high-risk phenotype within IMS-IMWG 2025 staging in newly diagnosed multiple myeloma.

Circulating tumor cells identify a disseminated genomic high-risk phenotype within IMS-IMWG 2025 staging in newly diagnosed multiple myeloma.

Journal: Leukemia
Published: June 09, 2026

Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001).

Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 27, 2026

Two Decades of Real-World Study in Newly Diagnosed Multiple Myeloma: Evolving Treatment and Outcomes in China with Reference to the United States.

Two Decades of Real-World Study in Newly Diagnosed Multiple Myeloma: Evolving Treatment and Outcomes in China with Reference to the United States.

Journal: Cancers
Published: October 23, 2025

Late and Durable Minimal Residual Disease Response Predicts Favorable Outcomes in Newly Diagnosed Multiple Myeloma.

Late and Durable Minimal Residual Disease Response Predicts Favorable Outcomes in Newly Diagnosed Multiple Myeloma.

Journal: International journal of cancer
Published: September 01, 2025

Ibrutinib alternating with three cycles of interval fludarabine, cyclophosphamide, and rituximab (FCR) in adults with untreated chronic lymphocytic leukaemia as time-limited regimen: a single-arm, multicentre phase 2 trial in China.

Ibrutinib alternating with three cycles of interval fludarabine, cyclophosphamide, and rituximab (FCR) in adults with untreated chronic lymphocytic leukaemia as time-limited regimen: a single-arm, multicentre phase 2 trial in China.

Journal: EClinicalMedicine
Published: August 15, 2025

Obinutuzumab plus bendamustine as first-line therapy for indolent B-cell lymphomas: a prospective multicenter open-label study.

Obinutuzumab plus bendamustine as first-line therapy for indolent B-cell lymphomas: a prospective multicenter open-label study.

Journal: MedScience
Published: August 06, 2025

Development of a Cytogenetic Double-Hit Model for Survival Prediction in Multiple Myeloma.

Development of a Cytogenetic Double-Hit Model for Survival Prediction in Multiple Myeloma.

Journal: Cancers
Published: July 28, 2025

Epidemiological characteristics of febrile seizure among children under 6 years old in Ningbo City from 2015 to 2021

Epidemiological characteristics of febrile seizure among children under 6 years old in Ningbo City from 2015 to 2021

Journal: Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
Published: June 13, 2025

Type I Interferon Pathway Activation Disrupts Monocyte Maturation and Enhances Immune Evasion in Multiple Myeloma.

Type I Interferon Pathway Activation Disrupts Monocyte Maturation and Enhances Immune Evasion in Multiple Myeloma.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: June 12, 2025

Optimal CAR-T cell therapy options for patients with multiple myeloma.

Optimal CAR-T cell therapy options for patients with multiple myeloma.

Journal: Chinese medical journal
Published: May 18, 2025

Long-term outcomes of CNCT19 chimeric antigen receptor T-cell therapy in relapsed or refractory aggressive B-cell lymphoma.

Long-term outcomes of CNCT19 chimeric antigen receptor T-cell therapy in relapsed or refractory aggressive B-cell lymphoma.

Journal: Chinese medical journal
Published: May 06, 2025

Long-term outcomes of CNCT19 chimeric antigen receptor T-cell therapy in relapsed or refractory aggressive B-cell lymphoma.

Long-term outcomes of CNCT19 chimeric antigen receptor T-cell therapy in relapsed or refractory aggressive B-cell lymphoma.

Journal: Chinese medical journal
Published: May 06, 2025
Showing 1-12 of 83

Last Updated: 09/26/2026